MHRA Field Safety Notices Issued on Medical Devices for 29 June-3 July 2026
The MHRA has published Field Safety Notices (FSNs) for the week of 29 June to 3 July 2026, detailing recalls and corrective actions for various medical devices. Manufacturers and distributors operating in the UK must review and act on relevant FSNs immediately to ensure compliance and patient safety.
London, United Kingdom — 07 July 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued Field Safety Notices (FSNs) for medical devices between 29 June and 03 July 2026. While the MHRA publishes these exclusively for information, manufacturers are legally obliged to act upon any FSNs they issue. This period's notices include devices from major manufacturers such as bioMérieux, Boston Scientific, Chalice Medical, Corin, Maquet Critical Care, Philips, and WEINMANN Emergency Medical Technology. The notices cover a range of products, including IVD kits, surgical tubing, prosthetic components, and anaesthesia systems, underscoring the broad scope of post-market surveillance activities.
These FSNs typically involve corrective actions such as product recalls, modifications, or advice for safe use, all aimed at mitigating risks associated with device performance or design. For instance, bioMérieux's ARGENE ENTEROVIRUS R‑GENE notice (MHRA reference: 40009416) pertains to an Enterovirus nucleic acid IVD kit, while Corin's TaperFit (MHRA reference: 40019584) addresses an uncoated femoral stem prosthesis. Each notice carries specific instructions for the affected batches or models, which are critical for distributors and healthcare providers to implement.
The proactive management of FSNs is a non-negotiable aspect of operating within the UK medical device market. Failure to promptly address FSNs can lead to significant regulatory enforcement actions, including fines, injunctions on product sales, and mandates for extensive product remediation. Beyond regulatory compliance, mishandling FSNs can severely damage brand reputation and erode clinician and patient trust, leading to measurable market share losses.
What this means for United Kingdom
UK manufacturers and distributors must maintain rigorous post-market surveillance systems capable of identifying and responding to FSNs within 48 hours of notification. Non-compliance with FSN directives can trigger MHRA investigations, potentially resulting in product delistings from NHS supply chains. Brand owners should review current insurance policies, as product liability costs related to FSN incidents can escalate quickly. Procurement teams need to assess supplier quality agreements to ensure that FSN management responsibilities are clearly defined, aiming for contractual guarantees on remediation timelines to protect supply continuity and minimise financial exposure from product returns, which can average 1-2% of annual turnover for affected lines.
This is a continuous regulatory requirement, with the MHRA regularly updating its FSN listings. Companies must therefore implement robust internal communication channels to ensure that FSNs are cascaded effectively from regulatory affairs departments to quality control, logistics, sales, and clinical support teams.
Many leading brands in this category are manufactured in partnership with Supplement Factory.